ENTERIC VALPROIC ACID
First Claim
1. An enteric valproic acid soft gelatin capsule comprising:
- (a) a fill material comprising valproic acid or divalproex sodium; and
(b) a capsule shell comprising a gelatin mass, film-forming water soluble polymer, an acid-insoluble polymer, and an aqueous solvent.
9 Assignments
0 Petitions
Accused Products
Abstract
An enteric valproic acid soft gelatin capsule, in which the enteric polymer is a component of the capsule shell rather than a coating, has been developed. The fill material comprises valproic acid or divalproex sodium and, optionally, one or more pharmaceutically acceptable excipients such as corn oil. The capsule shell is prepared from a mass comprising a film-forming polymer, an acid insoluble polymer, an aqueous solvent, and optionally a plasticizer. Suitable film-forming polymers include gelatin. Suitable acid-insoluble polymers include acrylic-acid/methacrylic acid copolymers. The acid-insoluble polymer is present in an amount from about 8% to about 20% by weight of the wet gel mass. The weight ratio of acid-insoluble polymer to film-forming polymer is from about 25% to about 50%. The aqueous solvent is water or an aqueous solution of alkalis such as ammonia or diethylene amine or hydroalcoholic solutions of the same. Suitable plasticizers include glycerin and triethylcitrate. The enteric soft gelatin capsule does not require an enteric coating and thus is not susceptible to the processing problems associated with enteric coated dosage forms. Enteric valproic acid soft gelatin capsules may be smaller in size and thus easier to swallow than currently available enteric coated tablets due to the presence of fewer ingredients, as well as smaller amounts of ingredients in the capsule shell.
23 Citations
31 Claims
-
1. An enteric valproic acid soft gelatin capsule comprising:
-
(a) a fill material comprising valproic acid or divalproex sodium; and
(b) a capsule shell comprising a gelatin mass, film-forming water soluble polymer, an acid-insoluble polymer, and an aqueous solvent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
- 28. A capsule comprising valproic acid, wherein the valproic acid is released following oral administration to a fasting individual to produce a Cmax between approximately 37.6 and 72.5 mg valproic acid/ml blood with a Tmax of between 1 and 4 hours.
Specification